Drug developed at U of M 'incredibly potent' in killing pancreatic cancer - Bring Me The News

Drug developed at U of M 'incredibly potent' in killing pancreatic cancer

Tumors that attack the pancreas are among the most lethal cancers. But a drug developed at the University of Minnesota has been used to kill those tumors in mice and could be tested on humans soon. The drug is made from a plant used in traditional Chinese medicine called the Thunder God Vine.
Author:
Publish date:

Researchers at the University of Minnesota's Masonic Cancer Center have developed a drug that kills pancreatic cancer tumors in mice. The success of the drug could lead to tests on humans as soon as next year.

The drug is called Minnelide (derived from Minnesota). It's made from a plant used in traditional Chinese medicine called the Thunder God Vine. The leader of the U of M's study tells Business Week the drug is "unbelievably potent in killing tumor cells."

Pancreatic cancer is one of the most lethal forms of cancer, with a median survival rate of six months after diagnosis. The Healthline blog reports the Minnesota study shows a protein that protects pancreatic tumors from other drugs is vulnerable to Thunder God Vine.

The National Institutes of Health has a page on Thunder God Vine. It says when it comes to the plant's cancer-fighting effects, the early evidence is promising but there are few studies in people.
The plant has also shown some promise as an arthritis treatment

Next Up

Related

U of M, Mayo Clinic cultivate close ties to drug companies

In part three in a series investigating drug company's financial relationships with health care practitioners, the Pioneer Press looks into the University of Minnesota and Mayo Clinic, two big organizations that are getting a growing share of industry money. Both organizations use the money for research and training, and both have processes in place to root out possible conflicts of interest.

U of M professor: Drugs aren't solution to kids' attention problems

A psychology professor from the University of Minnesota is making waves with an article in the Sunday New York Times. L. Alan Sroufe says medicating children is a misguided approach to treating attention disorders. "Putting children on drugs does nothing to change the conditions that derail their development in the first place," he writes.